PLUS1
41.50
-1.15 (-2.7%)
-1.15 (-2.7%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| FibroGen Inc | FGEN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Previous Close | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -1.15 | -2.7% | 41.50 | 41.03 | 42.90 | 42.73 | 42.65 | 18:33:19 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 41.50 | 42.01 | 0.51 | 1.21% | 3 | 2 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6,010 | 536,396 | $ 41.78 | $ 22,412,557 | 581,786 | 22.65 - 48.95 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:58:09 | formt | 200 | $ 41.50 | USD |
FibroGen Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 3.70B | 89.10M | 77.67M | $ 256.58M | $ - | -0.96 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
FibroGen News
| Date | Time | Source | News Article |
|---|---|---|---|
| 8/06/2020 | 16:19 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 8/06/2020 | 16:12 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/06/2020 | 16:07 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/06/2020 | 16:02 | GlobeNewswire Inc. | FibroGen Reports Second Quarter 2020 Financial Results |
| 8/06/2020 | 16:01 | GlobeNewswire Inc. | FibroGen Announces New Appointments to its Board of.. |
| 7/28/2020 | 19:34 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 7/23/2020 | 07:00 | GlobeNewswire Inc. | FibroGen to Report Second Quarter 2020 Financial Results |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FGEN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 40.50 | 43.26 | 40.20 | 41.74 | 388,416 | 1.00 | 2.47% |
| 1 Month | 41.52 | 45.99 | 40.20 | 43.11 | 469,321 | -0.02 | -0.05% |
| 3 Months | 35.72 | 45.99 | 32.12 | 39.01 | 654,839 | 5.78 | 16.18% |
| 6 Months | 46.20 | 47.48 | 22.65 | 37.35 | 680,621 | -4.70 | -10.17% |
| 1 Year | 45.26 | 48.95 | 22.65 | 39.27 | 678,641 | -3.76 | -8.31% |
| 3 Years | 34.90 | 68.55 | 22.65 | 45.72 | 644,455 | 6.60 | 18.91% |
| 5 Years | 23.87 | 68.55 | 14.38 | 38.84 | 557,218 | 17.63 | 73.86% |
FibroGen Description
| FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. |
